- Wu, Yiqian;
- Huang, Ziliang;
- Liu, Yahan;
- He, Peixiang;
- Wang, Yuxuan;
- Yan, Liyanran;
- Wang, Xinhui;
- Gao, Shanzi;
- Zhou, Xintao;
- Yoon, Chi;
- Sun, Kun;
- Situ, Yinglin;
- Ho, Phuong;
- Zeng, Yushun;
- Yuan, Zhou;
- Zhu, Linshan;
- Zhou, Qifa;
- Zhao, Yunde;
- Liu, Thomas;
- Kwong, Gabriel;
- Chien, Shu;
- Liu, Longwei;
- Wang, Yingxiao
There remains a critical need for the precise control of CRISPR (clustered regularly interspaced short palindromic repeats)-based technologies. Here, we engineer a set of inducible CRISPR-based tools controllable by focused ultrasound (FUS), which can penetrate deep and induce localized hyperthermia for transgene activation. We demonstrate the capabilities of FUS-inducible CRISPR, CRISPR activation (CRISPRa), and CRISPR epigenetic editor (CRISPRee) in modulating the genome and epigenome. We show that FUS-CRISPR-mediated telomere disruption primes solid tumours for chimeric antigen receptor (CAR)-T cell therapy. We further deliver FUS-CRISPR in vivo using adeno-associated viruses (AAVs), followed by FUS-induced telomere disruption and the expression of a clinically validated antigen in a subpopulation of tumour cells, functioning as training centers to activate synthetic Notch (synNotch) CAR-T cells to produce CARs against a universal tumour antigen to exterminate neighboring tumour cells. The FUS-CRISPR(a/ee) toolbox hence allows the noninvasive and spatiotemporal control of genomic/epigenomic reprogramming for cancer treatment.